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The hepatitis C virus (HCV) genome codes for highly
mannosylated envelope proteins, which are naturally
retained in the endoplasmic reticulum. We found that
the HCV envelope glycoprotein E2 binds the dendritic
cell-specific intercellular adhesion molecule 3-grabbing
nonintegrin (DC-SIGN) and the related liver endothelial
cell lectin L-SIGN through high-mannose N-glycans.
Competing ligands such as mannan and an antibody
directed against the carbohydrate recognition domains
(CRD) abrogated binding. While no E2 interaction with
distant monomeric CRDs on biosensor chips could be
detected, binding is observed if CRDs are closely seeded
(Kd  48 nM) and if the CRD is part of the oligomeric-
soluble extracellular domain of DC-SIGN (Kd  30 nM).
The highest affinity is seen for plasma membrane-ex-
pressed DC-SIGN and L-SIGN (Kd  3 and 6 nM, respec-
tively). These results indicate that several high-man-
nose N-glycans in a structurally defined cluster on E2
bind to several subunits of the oligomeric lectin CRD.
High affinity interaction of viral glycoproteins with oli-
gomeric lectins might represent a strategy by which
HCV targets to and concentrates in the liver and infects
dendritic cells.
Hepatitis C virus (HCV)1 is the major causative agent of
non-A, non-B hepatitis throughout the world with more than
170 million people infected (1). Contamination with infected
blood by injecting drug users is the primary risk factor for
acquiring HCV infection. The majority of infected patients are
unable to clear the virus, and many develop chronic liver dis-
ease, cirrhosis, and hepatocellular carcinoma (2). Replication of
the HCV genome could be demonstrated in vivo and in vitro in
liver hepatocytes (3, 4) and hematopoietic cells including den-
dritic cells and B cells (5, 6). However, the molecular mecha-
nism by which the virus targets to these sites of replication,
notably in the liver, is not known.
HCV is a small, enveloped, plus-strand RNA virus belonging
to the family flaviviridae and genus hepacivirus. The HCV
RNA genome is 9600 nucleotides in length and encodes a single
polyprotein that is post-translationally cleaved into up to 10
polypeptides including three structural proteins (core, E1, and
E2), located at the N terminus, and five nonstructural proteins
(1, 7, 8). Shortly after translocation into the endoplasmic retic-
ulum (ER), oligosaccharide transferase catalyzes addition of
Glc3Man9GlcNAc2 complexes at up to 6 (E1) and 11 (E2)
N-glycosylation sites (for review see Ref. 9). Glucose residues
are removed by glucosidases I and II, and correctly folded
proteins are released from ER chaperones calnexin and calre-
ticulin (10–13). The transmembrane domains of E1 and E2 are
responsible for both heterodimerization (14) and retention of
the glycoproteins in a high-mannose EndoH-sensitive glyco-
form in the ER (15–17). By analogy to other flaviviruses it is
assumed that HCV capsids bud from the cytoplasm into the ER
and that enveloped particles follow the secretion pathway
through the Golgi. However, attempts to produce secreted HCV
particles in vitro have not been successful so far (18–20), and it
is not known if E1 and E2 on mature infectious virions possess
a high-mannose, complex, or mixed glycosylation.
Several receptors have been proposed that could play a role
in HCV entry into hepatocytes. The low density lipoprotein
(LDL) receptor has been shown to mediate HCV internalization
via binding to virus-associated LDL particles (21, 22). A second
putative HCV receptor, the tetraspanin CD81, has been iden-
tified as a high affinity binding receptor (1.8 nM) for soluble
recombinant E2 from HCV genotype 1a (23, 24). CD81 and LDL
receptor are expressed in most cell types and thus likely do not
account for the hepatic tropism of the virus. Furthermore E2
binds to the hepatoblastoma cell line HepG2, which does not
express CD81 (25). More recently two novel E2 binding recep-
tors have been identified on HepG2 cells, the scavenger recep-
tor type B class I (SR-BI) (25) and the galactose binding C-type
lectin asialoglycoprotein receptor (26). The lack of an efficient
cell culture model has precluded functional confirmation of
these receptor candidates at the level of virus entry.
It has recently been shown that C-type mannose binding
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lectins DC-SIGN and L-SIGN (DC-SIGNR) can be used by viral
and bacterial pathogens including HIV (27), Ebola virus (28),
cytomegalovirus (29), and mycobacterium tuberculosis (30–32)
to facilitate infection. Both lectins can act either in cis, by
concentrating virus on target cells, or in trans, by transmission
of bound virus to a target cell expressing appropriate entry
receptors. DC-SIGN and L-SIGN are homotetrameric type II
membrane proteins, which can bind mannose residues of viral
glycoproteins through a C-terminal carbohydrate recognition
domain (CRD) (33, 34). DC-SIGN is an adhesion receptor for
ICAM-2 and ICAM-3 on T cells (35) and is expressed in den-
dritic cells, some subsets of macrophages, and placenta (36–
38). The physiological role of L-SIGN is not known yet. High-
mannose N-glycans have been shown to be important for
attachment of HIV to DC-SIGN and L-SIGN (34, 39), and
oligomerization of the extracellular domain was shown to be
implicated in high affinity binding of glycopeptides (33).
In this report we show that DC-SIGN and L-SIGN are two
novel HCV envelope binding receptors. High affinity interac-
tion of E2 with both lectins depends on the presence of high-
mannose N-glycans on the viral glycoprotein and oligomeriza-
tion of the C-type lectin CRD. HCV interaction with L-SIGN
might represent a strategy by which the virus targets to and
concentrates in the liver. Indeed its localization on the endo-
thelium lining hepatic sinusoids (40, 41) makes it an interest-
ing candidate for the capture of enveloped hepatotropic viruses
like HCV.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Human antibodies were produced as pre-
viously described (42), and mouse antibodies were a gift from J. Du-
buisson. Human antibodies CBH2, CBH4B, CBH4G, CBH5, and CBH7
and mouse antibody H33 are directed against conformation-dependent
epitopes, and H52 and CBH17 against linear epitopes. As control,
human and mouse isotype control antibodies R04 and IgG2a were used.
Phycoerythrin-conjugated mouse anti-DCSIGN FAB161B and mouse
anti-LSIGN FAB162P were purchased from R&D Systems. 1B10 is a
DC-SIGN mouse conformation antibody directed against the DC-SIGN
CRD and was described previously (29). Anti-FLAG antibody M2 was
purchased from Sigma. HIV gp140 was produced in Semliki Forest
Virus (SFV) vector-infected baby hamster kidney (BHK) cells as de-
scribed previously (43). Cloning of DC-SIGN cDNA was described pre-
viously (29) and DC-SIGNR (L-SIGN) cDNA was a gift from Dr. R. W.
Doms, (University of Pennsylvania, Philadelphia, PA). HCV envelope-
encoding plasmid pCAV711V was a gift of T. Miyamura, (National
Institute of Infectious Diseases, Tokyo, Japan) (44).
Cell Lines and C-type Lectin Expression—HelaP4DC were generated
by transduction with a DC-SIGN expressing lentiviral vector as previ-
ously described (45). Hek293T (2 107 cells) cells were transfected with
40 g of DC-SIGN or L-SIGN expression plasmids using standard
phosphate calcium transfection method as described previously (46).
HeLaP4DC and Hek293T cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum
(FCS) and 1% penicillin/streptomycin. BHK cells were cultured in
BHK-21 Glasgow’s modified Eagle’s medium with 5% FCS, 1% penicil-
lin/streptomycin, 20 mM Hepes, and 10% tryptose phosphate broth. All
products used for cell cultures were from Invitrogen.
Construction of Soluble E2 (sE2) Expression Plasmid—Plasmid
pCAV711V was used as template to generate recombinant SFV coding
for the soluble transmembrane (TM)-deleted form of E2. The sequence
encoding for the ectodomain of HCV envelope protein (E2, amino acids
(aa) 384–710) was amplified by PCR (Pwo DNA Polymerase, Roche
Applied Science) using the sense primer 5-ATATTGCGCGCATGTTC-
ATGCCTTCTTCTTTT-3 and the antisense primer 5-TTTATATTAT-
GCATTCACTTGTCATCGTCATCCTTGTAGTCGCCGACGACCGCCG-
ACCCTATACC-3. The antisense primer used for E2 codes for the
FLAG tag (DYKDDDDK) peptide sequence. The amplified sequence
was digested by BssHII and NsiI and introduced into respective sites of
the pSFV2 vector (47–49). The recombinant plasmid pSFVsE2 was
sequenced through the E2 coding region.
Expression and Purification of Recombinant Proteins—Recombinant
SFVsE2 was produced by electroporation of in vitro synthesized vector
RNA into BHK cells. Soluble proteins were produced by infection of
BHK cells by SFVsE2 (multiplicity of infection 50) as previously de-
scribed (43). At 6 h postinfection, medium was replaced by 0% FCS
Glasgow’s modified Eagle’s medium for standard protein purification or
for the production of radiolabeled sE2 by 0% FCS methionine/cysteine-
free DMEM (ICN Biomedicals) prior to addition of 200 Ciml1
[35S]cysteine and methionine (Pro-Mix 35S, Amersham Biosciences).
Synthesis of sE2 was continued up to 24 h postinfection in the presence
(sE2man) or absence (sE2cpx) of -manosidase I and II inhibitors 1-de-
oxymannojirimycin hydrochloride (DMJ, 1 mM, Calbiochem) and swain-
sonine (5 mM, Sigma). Supernatants were clarified and concentrated in
a 10-kDa concentration column (Biomax, Millipore) prior to purification
on anti-FLAG monoclonal antibody M2 beads and elution by soluble
FLAG peptide (DYKDDDDK, 150 ng l1) according to instructions of
the supplier (Sigma). For surface plasmon resonance experimentations,
a supplementary dialysis against phosphate-buffered saline (Bi-
ome´rieux) was realized overnight at 4 °C using a Slide-A-Lyzer Cas-
sette (Pierce) to eliminate free peptides and purification buffer.
The cDNA coding for the CRD (corresponding to amino acids 254–
404) and for the extracellular domain (ECD) of DC-SIGN (correspond-
ing to amino acids 66–404) of DC-SIGN were obtained by PCR, cloned
into pET15b (Novagen) and verified by DNA sequencing. The plasmids
were subsequently used to transform Escherichia coli C41(DE3), and
proteins were expressed as inclusion bodies. Inclusion bodies prepara-
tion and refolding of the proteins have been done by dilution and
dialysis as already described (33). Purification of refolded DC-SIGN
CRD and DC-SIGN ECD were achieved by affinity chromatography in
two steps (Ni2 column equilibrated in 25 mM Tris-Cl, pH 7.8, 150 mM
NaCl, and 4 mM CaCl2 and eluted with a linear gradient of imidazole
followed by a mannose-agarose column equilibrated in 25 mM Tris-Cl,
pH 7.8, 150 mM NaCl, 4 mM CaCl2, and eluted with the same buffer
lacking CaCl2 but supplemented in 10 mM EDTA as described (29)).
Pooled fractions were then concentrated and dialyzed against 25 mM
Tris, pH 7.8, 150 mM NaCl, and 4 mM CaCl2.
Deglycosylation and Protein Analysis—Crude protein extracts were
denatured in 0.5% SDS, 1% -mercaptoethanol at 100 °C for 5 min, and
followed by incubation overnight at 37 °C in G7 buffer (50 mM sodium
phosphate, pH 7.5, Biolabs), Nonidet P-40 buffer (1% Nonidet P-40,
Biolabs) containing endoglycosidase H (2 milliunits, Roche Applied
Science), or peptide:N-glycosidase F (PNGase F) (1000 units, Biolabs).
To obtain native deglycosylated sE2, the denaturing step was omitted
from this procedure. Mock-treated sE2 was prepared without PNGase F
as control in binding experiments. Proteins were analyzed by SDS-
PAGE (Nupage Novex Bis-Tris Gels, Invitrogen). Gels were either fixed,
dried and exposed to Biomax MR1 film (Kodak), or stained with Novex
Colloidal Blue Staining Kit (Invitrogen) according to the supplier’s
instructions.
Immunodetection of DC-SIGN, L-SIGN, and sE2 Proteins—DC-
SIGN and L-SIGN were detected by fluorescent-activated cell sorting
(FACS) using, respectively, phycoerythrin-conjugated anti-DC-SIGN
(FAB161B) and anti-L-SIGN (FAB162P) antibodies. Cells were washed
in FCS-free DMEM medium and resuspended in FACS analysis buffer
(1% bovine serum albumin, 0.2% globulin, 0.1% sodium azide (all from
Sigma)) followed by incubation with primary antibodies at a 1/50-
dilution for 30 min at 4 °C. Cells were washed and fixed with paraform-
aldehyde (3.2%) prior to FACS analysis (BD Biosciences and data proc-
essing with CellQuest software (Becton Dickinson). For Western
blotting, proteins were harvested (48-h cells post-transfection for
Hek293T-L-SIGN) in lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100) supplemented with protease inhibitors
(Roche Applied Science). Cell lysates or sE2 solution was subjected to
SDS-PAGE and transferred onto a Immobilon P membrane (Millipore).
Incubation with primary antibodies 1B10 (anti-DC-SIGN; 2 gml1),
FAB162P (anti-L-SIGN; 1 gml1), MAbM2 (anti-FLAG; 4 gml1)
was followed by incubation with an anti-mouse horseradish peroxidase-
conjugated secondary antibody NA931V (Amersham Biosciences) (1/
1000). Bound antibody was detected by exposure to enhanced chemilu-
minescence detection reagents (Supersignal, Pierce) and analyzed by a
video acquisition system (Intelligent Dark Box II; Fuji) and Image
Gauge software (Fuji).
For immunoprecipitation of radiolabeled sE2, crude protein extract
was incubated with 60 l of protein G-Sepharose (50% suspension in A
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA (Invitrogen),
0.2% Nonidet P-40 (Fluka)) and mouse or human monoclonal isotopic
antibodies (15 gml1) for 30 min at 4 °C. Different primary antibodies
(15 gml1) were added to supernatant and placed overnight under
agitation at 4 °C. After a 5-s spin at 13,000 rpm, the pellets were
washed three times with A buffer and then B buffer (10 mM Tris-HCl,
pH 7.5, 500 mM NaCl, 2 mM EDTA, 0.2% Nonidet P-40) and C buffer (10
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mM Tris-HCl, pH 7.5). Beads were then resuspended in Laemmli buffer
and heated at 100 °C for 3 min, and samples were separated by SDS-
PAGE. Subsequently, gels were fixed, dried, and exposed to Biomax
MR1 film (Kodak).
Surface Plasmon Resonance-based DC-SIGN CRD and ECD Binding
Assay—Flow cells of a Biacore B1 sensor chip were activated with a
mixture of 0.2 M N-ethyl-N-(3-dimethyl-aminopropyl)-carbodiimide hy-
drochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) as de-
scribed (29). Flow cell one was then blocked with 50 l of 1 M ethanol-
amine, pH 8.5, and served as a control surface. The other ones were
treated with the CRD (5–50 gml1) or the ECD (2.5 gml1) of
DC-SIGN, both in 10 mM acetate buffer, pH 4. Different amounts of
immobilized protein were obtained by varying the injected volume (see
“Results”). Remaining activated groups were blocked with 50 l of 1 M
ethanolamine, pH 8.5. For binding assays, either sE2man or sE2cpx
were diluted in running buffer (25 mM Tris, 150 mM NaCl, 4 mM CaCl2,
pH 7.8) and injected (at 15 lmin1) over the DC-SIGN-activated
sensorchip for 15 min, after which the formed complexes were washed
with running buffer. Surfaces were regenerated by a 5-min pulse of 100
mM EDTA. In some cases, surface was made with sE2man. For that
purpose, sE2man, 5 gml1 in 10 mM acetate buffer, pH 4, was injected
over an EDC/NHS-activated B1 sensorchip. Binding assay was per-
formed with the conditions described above, DC-SIGN being injected
over the sE2man surface.
sE2 Binding on Plasma Membrane-expressed DC-SIGN and
L-SIGN—Assays were performed on 3  105 DC-SIGN or L-SIGN
expressing cells in 200 l of FACS buffer supplemented with 1 mM
CaCl2 and 2 mM MgCl2 and
35S-labeled sE2 protein at various concen-
trations. sE2 was incubated for 2 h at 4 °C, and unbound radioactivity
was removed by three washes with FACS buffer. Cell pellets were
resuspended in FACS buffer prior to addition of optiphase supermix
solution (Wallac), and bound activity was counted in a 1450 Microbeta
Trilux  counter (Wallac). For inhibition assays, cells were preincu-
bated with inhibitors in FACS buffer for 15 min at 4 °C before addition
of labeled envelope protein preparations containing inhibitor. Inhibi-
tors were used at 20 gml1 final concentration (mannan (Sigma),
EGTA (Sigma), 1B10, isotype control IgG, HIV gp140). The native
deglycosylated sE2 protein was compared with a mock-treated sE2
protein (incubated in buffer without PNGase F). Saturation binding
was assayed by the addition of increasing amounts of labeled sE2
protein. Data were analyzed using Prism software (GraphPad), and the
specific binding curves were fit by nonlinear regression after subtract-
ing nonspecific binding, i.e. sE2man binding to HeLa cells.
RESULTS
Expression and Purification of High-mannose and Complex
E2 Glycoforms—The HCV envelope glycoproteins are retained
in the ER in a high-mannose glycoform by the action of their
TM domain. When produced as soluble proteins, deleted of the
TM domain, the proteins acquire complex glycosylation in the
Golgi. Whether E2 on HCV virions acquires complex glycosy-
lation is not known at present. To study interaction of HCV E2
with cell surface receptors, we expressed the extracellular do-
main of E2 (sE2), corresponding to aa 384–710 of isolate NIHJ1
fused to a 9-aa FLAG peptide at the C terminus (Fig. 1). We
used the defective SFV vector as it allows high level expression
of functional virus glycoproteins (43, 50). To mimic the glyco-
sylation pattern observed on ER-retained wild-type E2, we
treated SFV-infected BHK cells with -mannosidase inhibitors
DMJ and Swainsonine. The resulting protein, sE2man (58
kDa) acquires only high-mannose N-glycans as evidenced by
sensitivity to endoglycosidase H (EndoH) digestion, resulting
in a 39-kDa protein (Fig. 2A). In contrast, sE2cpx synthesized
in untreated cells acquired complex glycosylation (65 kDa) and
was mainly EndoH-resistant (Fig. 2A). A small shift in molec-
ular weight was observed for EndoH-treated sE2cpx suggesting
that a small fraction of glycosylation sites remained in their
high-mannose EndoH-sensitive form. However both sE2man
and sE2cpx were sensitive to PNGase F digestion, which
cleaves both complex and high-mannose N-glycans at the Asn-
GlcNac bond, resulting in a deglycosylated 37-kDa protein. To
evaluate the role of high-mannose N-glycans in attachment to
cell surface molecules, we deglycosylated sE2man by PNGase F
treatment under non-denaturing conditions (Fig. 2A, PNGase
F native). sE2 synthesized in hepatocytic cell lines HepG2 and
Huh7 had a complex EndoH-resistant glycosylation phenotype
similar to sE2 produced in BHK cells (data not shown).
Soluble E2 Proteins Are Recognized by Conformation-
dependent Monoclonal Antibodies—We analyzed whether
35S-labeled sE2man and sE2cpx were correctly folded by im-
munoprecipitation analysis with a series of linear and confor-
mation-dependent mouse and human monoclonal antibodies
(Fig. 2B). All antibodies directed against conformation-depend-
ent and linear epitopes, but not isotype control antibodies,
recognized sE2man and sE2cpx. Correct folding of sE2 ex-
pressed in the SFV system is underscored by the lack of reten-
tion and degradation by the ER quality control machinery and
efficient transition of sE2 to the Golgi (data not shown). For
subsequent binding experiments sE2man and sE2cpx were
purified by immunoaffinity using FLAG tag beads. Fig. 2C
shows that sE2-enriched crude supernatants of SFV-infected
cells can be purified by this system resulting in a greater than
90% pure sE2 preparation.
Soluble E2 Binds to DC-SIGN and L-SIGN—C-type man-
nose lectins DC-SIGN and L-SIGN were expressed on the sur-
face of HeLa cells or HEK293T cells and could be detected by
FACS and Western blot (Fig. 3A). DC-SIGN and L-SIGN mono-
mers migrate at an apparent molecular mass of 45.5 and 48.5
kDa, respectively. DC-SIGN multimers could also be detected,
in accordance with the capacity of both lectins to form dimers
and tetramers (33). Both purified 35S-labeled sE2cpx and
sE2man were able to bind to DC-SIGN and L-SIGN but not to
control cells (Fig. 3B). However at equimolar concentrations of
radiolabeled sE2man and sE2cpx, an average of 10–20-fold
higher binding signal was obtained for sE2man. This suggests
that the presence of high-mannose, EndoH-sensitive glycosyla-
tion on sE2man facilitated binding. We further sought to iden-
tify the specificity of this interaction by testing several known
inhibitors of ligand binding to DC-SIGN or L-SIGN. The lectin
ligand mannan and the HIV envelope glycoprotein gp140 effi-
ciently inhibited binding of sE2man and sE2cpx to both lectins
(Fig. 4, A and B). Deglycosylation of sE2man greatly reduced
binding of E2 to both lectins. In addition, the CRD-specific
antibody 1B10 inhibited binding of sE2man and sE2cpx to
DC-SIGN. Altogether these results identify DC-SIGN and L-
SIGN as novel receptor molecules for HCV binding and suggest
a pivotal role of high-mannose N-glycans as binding motifs on
HCV E2.
FIG. 1. Generation of epitope-tagged soluble HCV glycoprotein
E2. The cDNA sequence corresponding to the ectodomain of E2 (aa
384–710; isolate NIHJ1) was inserted into the Semliki Forest virus
expression vector. Transmembrane and C-terminal domains were re-
placed by the FLAG tag peptide. The VSV-G signal peptide (VSV-G PS)
was added in the N-terminal domain of soluble E2 protein (sE2) (44).
The triangles indicate the 10 putative glycosylation sites of E2NIHJ1.
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sE2 Interaction with Monomeric and Oligomeric CRD of DC-
SIGN—Surface plasmon resonance analysis (Biacore) was used
to further investigate the E2/DC-SIGN complex formation (Fig.
5). In a first approach, the ECD of DC-SIGN was immobilized
on the sensorchip to a level of 700 RU, and sE2 was injected in
the fluid phase. Fig. 5A shows the binding curves when a range
of concentration (see the figure legends) of either sE2man or
sE2cpx was injected over the surface. Visual inspection of the
binding curves showed that while sE2man injection over the
surface gave rise to typical sensorgrams, sE2cpx did not
show significant binding activity. Injection of identical concen-
trations of sE2man or sE2cpx over a control surface that un-
derwent exactly the same chemistry (EDC/NHS activation,
ethanolamine blocking), except from functionalization with
DC-SIGN, did not produced any binding signal (data not
shown). The formed complexes were fully dissociated with
EDTA, indicating that ligand binding presumably involved an
interaction between mannose residues on the viral glycoprotein
and the CRD of DC-SIGN in a Ca2-dependent manner, as
expected for this C-type lectin. However, when sE2man or
sE2cpx were injected over a surface made with 200 RU of the
CRD (Fig. 5B, “low density” surface) no binding was observed.
This result suggested that binding can only be achieved when
several CRDs are clustered in close proximity as it occurs in the
FIG. 2. sE2 can be produced and purified with high-mannose or predominantly complex glycosylation. A, 35S-labeled sE2 was
produced in BHK cells in the presence or absence of mannosidase inhibitors (1 mM DMJ and 5 mM Swainsonine) (sE2man or sE2cpx, respectively).
Secreted proteins were subjected to digestion with EndoH or PNGase F and immunoprecipitated with an anti-FLAG epitope monoclonal antibody.
sE2 could be partially deglycosylated with PNGase F under non-denaturing conditions (PNGase F native). B, antigenicity of sE2cpx and sE2man.
Human mAb (CBH) and mouse mAb (H) directed against E2 conformation-dependent (CBH2, CBH4B, CBH4G, CBH5, CBH7, H33) and linear
epitopes (CBH17, H52, anti-FLAG) were used to immunoprecipitate non-denatured 35S-labeled sE2 protein. C, purification of sE2cpx and sE2man.
Both sE2 proteins were purified under non-denaturing conditions by immunoaffinity using FLAG tag-Sepharose beads and elution with a FLAG
peptide. The purity of sE2 was greater than 90% as evaluated by Coomassie Blue staining, and the specificity was controlled by Western blotting
using the mouse mAb anti-FLAG.
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full-length DC-SIGN ECD. To investigate this possibility the
binding of sE2man to DC-SIGN CRD was analyzed using a
surface made with 1000 RU of the CRD (“high density” sur-
face). Such a surface displayed high binding capacity (Fig. 5C),
suggesting that binding is only achieved by the clustering of
several CRD. The binding curves obtained have been fitted to
various kinetic models. However, none of them could be satis-
fyingly fitted to any of the experimental data. This suggests a
complex binding mode, a point consistent with the view that
multiple CRDs cooperate to bind their ligand. Thus, where
possible, equilibrium data were extracted from the sensorgram
at the end of each injection and used to calculate the equilib-
rium dissociation constant independently of the kinetic analy-
sis. This analysis returned a dissociation constant of 48 nM
(Fig. 5D) and 30 nM (Fig. 5E) for the binding of sE2man to the
ECD and the CRD high density, respectively. To further sup-
port the fact that clusters of CRD are required to interact with
sE2, the CRD or the full-length ECD (which displays four
clustered CRD) was injected over a surface made up with
sE2man. As expected from the above hypothesis, the ECD
efficiently bound to sE2man, while the isolated CRD produced
virtually no binding response.
FIG. 3. HCV E2 binds to C-type lectins DC-SIGN and L-SIGN. A, expression of DC-SIGN in the HeLa P4DC cell line and L-SIGN in
HEK293T cells was detected by FACS and Western blotting under non-reducing conditions. B, 35S-labeled sE2cpx and sE2man were bound to
HelaP4DC (4 nM sE2 added to cells) and HEK293T-L-SIGN (25 nM sE2 added to cells). The data are representative of three independent
experiments. Values are given as the mean of duplicates  S.E.
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sE2man Binds with High Affinity to Oligomeric Plasma
Membrane-expressed DC-SIGN and L-SIGN—The dissociation
constant of sE2man binding to DC-SIGN and L-SIGN was
determined on lectin-expressing cells (Fig. 6). Saturation ex-
periments revealed a dissociation constant of 3 nM for DC-
SIGN (Fig. 6A) and 6 nM for L-SIGN (Fig. 6B). At 10–20 nM
concentrations, when sE2man had reached saturation binding,
the sE2cpx binding curve was still linear (data not shown),
indicating that the dissociation constant of sE2cpx is higher
than that of sE2man. However, we were unable to produce
sufficient quantities of purified sE2cpx to obtain saturation of
all binding sites on DC-SIGN- or L-SIGN-expressing cells. The
low binding of sE2cpx is likely due to binding of single high-
mannose N-glycans on sE2cpx to the lectin CRD, while sE2man
might interact with the tetrameric CRD via several high-man-
nose N-glycans. Altogether binding results obtained with
sE2man and sE2cpx indicate that multiple high-mannose N-
glycans on HCV E2 are required to engage in a high affinity
complex with tetrameric CRD of C-type lectins DC-SIGN and
L-SIGN.
DISCUSSION
HCV glycoprotein E2 is highly mannosylated and retained in
the ER through its TM domain (15–17). Previous studies indi-
cate that TM-deleted E2 alone can assume a correct folding
conferring binding to receptor candidate molecules CD81 (23)
and SR-BI (25) and conformation-dependent antibodies (42).
During synthesis in the ER, only correctly folded glycoproteins
are released from molecular chaperones BIP, calnexin, or cal-
reticulin before proceeding to the Golgi compartment (10, 12).
FIG. 4. Specificity of sE2cpx and sE2man binding to DC-SIGN and L-SIGN. Several known inhibitors and competitors for C-type lectin
binding were used in a binding assay with 35S-labeled sE2cpx and sE2man. A, specificity of binding to DC-SIGN. sE2cpx (20 nM) or sE2man (3 nM)
were incubated on HelaP4DC cells in the presence of mannan (20 gml1), EGTA (5 mM), HIV gp140 (150 nM), or mAb 1B10 directed against the
CRD of DC-SIGN (20 gml1) and a control IgG. Values are given as fold increase over background. Deglycosylation of sE2man (PNGase F native)
was used to control that binding was mediated by E2 N-glycans. Mean cpm values for negative control HeLa cells were 32 cpm (sE2cpx) and 82
cpm (sE2man). B, specificity of sE2cpx and sE2man binding to L-SIGN. sE2cpx (20 nM) or sE2man (3 nM) were incubated in the presence of mannan
(20 gml1), EGTA (5 mM), HIV gp140 (150 nM). Deglycosylation of sE2man (PNGase F native) was used to control that binding was mediated by
E2 N-glycans. Mean cpm values for negative control HEK293T cells were 77 cpm (sE2cpx) and 141 cpm (sE2man). The data are representative of
three independent experiments. Values are given as the mean of duplicates  S.E.
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Proteins that are not correctly folded are retained by the qual-
ity control machinery in the ER and eventually become de-
graded. Time course experiments show that sE2man and
sE2cpx are efficiently secreted from SFV-infected BHK cells
(data not shown). No accumulation of intracellular aggregates
is observed and after 6 h postentry into the ER, 90% of sE2
has migrated to the Golgi compartment as judged by the ac-
quisition of complex glycosylation for sE2cpx. Furthermore,
secreted sE2man and sE2cpx are recognized by a panel of
conformation-dependent human monoclonal antibodies (42),
including MAbCBH2 and MAbCBH5, which are able to block
virus binding to CD81 (42). Interestingly, it was recently de-
scribed that MAbCBH2 exclusively reacts with E2 when coex-
pressed with E1, implying that MAbCBH2 recognizes an E2
heterodimer-specific epitope (51). We do not confirm this find-
ing as E2 is recognized by MAbCBH2 in the absence of E1
expression suggesting that the formation of the CBH2 epitope
does not strictly depend on E1 coexpression and heterodimer-
ization. However, it has to be noted that the E2 protein used in
this study (genotype 1b; isolate NIHJ1) (44, 52, 53) is different
from those used by Cocquerel et al. (51) and that recognition by
MAbCHB2 could be isolate-specific.
We used TM-deleted soluble E2 that has either high-man-
nose EndoH-sensitive N-glycans (sE2man) or mixed, predomi-
nantly EndoH-resistant N-glycans (sE2cpx). Our results show
that C-type lectins DC-SIGN and L-SIGN are two novel HCV
envelope binding receptors, which bind E2 with high affinity
(Kd  3 and 6 nM, respectively). Like HCV E2, HIV gp120 has
been described to bind with high affinity to DC-SIGN (Kd  1.5
nM) (36). sE2cpx has only few EndoH sensitive high-mannose
N-glycans, which allow a weak but significant binding to DC-
SIGN and L-SIGN, while sE2man strongly binds to both lec-
tins. These results are in keeping with a recent paper (39)
FIG. 5. Surface plasmon resonance analysis of sE2/DC-SIGN
interactions. The sE2 glycoproteins, used at concentrations of 400,
200, 100, 50, 25, 12.5, and 6.25 nM, were injected for 15 min over
DC-SIGN-activated surfaces at a flow rate of 15 lmin1, after which
running buffer alone was injected. A, overlay of sensorgrams showing
binding of either sE2man or sE2cpx to ECD surface. B, overlay of
sensorgrams showing binding of sE2 (either sE2man or sE2cpx) to low
density CRD surface (200 RU immobilized). C, overlay of sensorgrams
showing binding of either sE2man or sE2cpx to high density CRD
surface (1000 RU immobilized). D, Scatchard plot of the equilibrium
binding data measured at the end of the sensorgrams for the CRD high
density-sE2man interaction. E, Scatchard plot of the equilibrium bind-
ing data measured at the end of the sensorgrams for the ECD-sE2man
interaction. F, overlay of sensorgrams showing binding of either the
ECD or the CRD of DC-SIGN (both at 250 nM) to immobilized 120 RU
of sE2man. Results are given as the mean of Kd values determined from
two independent experiments.
FIG. 6. Saturation binding of sE2man on DC-/L-SIGN. A, in-
creasing amounts of 35S-radiolabled sE2man protein were added to
HeLa cell line constitutively expressing DC-SIGN. The saturation bind-
ing curve was fit by nonlinear regression after subtracting nonspecific
binding, i.e. binding of sE2man to HeLa cells, from total binding to
HeLa-DC-SIGN cells. B, increasing amounts of 35S-radiolabled sE2man
protein was added to Hek293T cells transiently transfected with an
L-SIGN-expressing plasmid. The saturation binding curve shown was
fit by nonlinear regression after subtracting nonspecific binding, i.e.
binding of sE2man to control cells, from total binding to L-SIGN. The
binding curves shown in A and B are representative of two independent
experiments each. Kd values (S.E.) were calculated using GraphPad
Prism Software, and Scatchard plots of the equilibrium binding data
are shown in the insets.
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showing that the presence of high-mannose N-glycans is the
principal determinant of virus glycoprotein interaction with
C-type lectins DC/L-SIGN. Structural analyses of the CRD of
L-SIGN in complex with a Man9 glycan support this interpre-
tation as they prove that only the outer trimannose branch
point of the glycan in its unmodified high-mannose form binds
to the CRD. The binding of the inner trimannose branch point
to the CRD is blocked due to steric hindrance caused by a clash
of Phe-325 of L-SIGN with a core N-acetyl-glucosamine of the
glycan (34). Deglycosylation of sE2man with PNGase F under
native conditions allowed us to partially remove the high-man-
nose N-glycans from sE2 indicating that the majority of the 10
E2 glycosylation sites are accessible at the surface of the solu-
ble E2 molecule without denaturation. The deglycosylated sE2
preparation bound three times less to DC/L-SIGN than
sE2man, but the residual high-mannose N-glycans still allowed
significant binding compared with control. At present we do not
know where these PNGase F-resistant N-glycans are located
and whether they are part of a preferential binding site.
In our experiments high affinity binding correlates with
close association of lectin CRDs, and we observe the highest
affinity for sE2man when the CRD is part of a plasma mem-
brane-expressed tetrameric lectin. This strongly suggests that
multiple contacts are made between several high-mannose N-
glycans on sE2man with the tetrameric CRD. In support of this
model are results obtained in the HIV model, where high-
mannose N-glycans were modeled on the structure of the tri-
meric envelope glycoprotein gp120. Results obtained by other
groups suggest that DC-SIGN interacts with high-mannose
N-glycans located on the outer surface of the envelope trimer in
clusters facing the cell (39, 54). Biochemical data further sup-
port the view that up to four high-mannose N-glycans in such
clusters might recognize the four CRD subunits of the lectin
tetramer (33). Structural data are now needed to analyze the
interaction of virus glycoprotein with lectin CRDs.
We speculate that DC-SIGN and L-SIGN might be molecular
determinants for tissue tropism of HCV based on a growing
body evidence. The virus is mainly transmitted by intravenous
injection (drug use, contaminated needle sharing, blood trans-
fusion) (55), and it is likely that HCV encounters circulating or
tissue-resident dendritic cells (DC). In keeping with this as-
sumption, replicating antigenomic HCV minus-strand RNA
has been detected in DC in vitro (6) and more importantly in
vivo (5, 56). Regarding the interaction with DC-SIGN it has
been shown that this lectin facilitates virus entry into DC in cis
by enhancing attachment of HIV (27), Ebola virus (28), cyto-
megalovirus (29), and Dengue virus2 to the cell, thereby in-
creasing the likelihood of interaction with specific entry recep-
tors. Besides playing a role in entry into DC, HCV E2
interaction with DC-SIGN might also be detrimental for the
interaction of DC with T cells during antigen presentation (35).
Deficiencies in allogenic stimulation of T cells have indeed been
observed in HCV-infected patients (56), but further studies
using infectious HCV patient serum or E1/E2-pseudotyped vi-
ruses (53) will be needed to explore the functional aspects of
HCV-DC-SIGN interaction.
Our results on E2 binding to L-SIGN might play an impor-
tant role in receptor-mediated targeting of HCV to the liver.
Indeed, the selective expression of L-SIGN in liver sinusoidal
cells is in favor of this hypothesis. Following contamination by
infected blood, HCV might bind to L-SIGN on sinusoidal endo-
thelial cells resulting in concentration of virions in the liver.
Productive infection of endothelial cells by HCV has not been
demonstrated, but L-SIGN could be responsible for the trans-
mission of bound virus to neighboring hepatocytes. This kind of
mechanism of trans-enhancement has been demonstrated more
than a decade ago for HIV transmission from DC to T cells (57)
and can be attributed to DC-SIGN (27). Internalization of HIV
might be important in this process as mutations of a dileucine
motif in the cytoplasmic domain of DC-SIGN have been shown
to abolish enhancement of HIV infectivity (58). In the case of
HCV, it is tempting to speculate that subsequent to interaction
with L-SIGN on endothelial cells, the virus could be transmit-
ted to hepatocytes where it uses a specific receptor for entry.
Candidates include CD81 (23), the scavenger receptor SR-BI
(25), the LDL receptor (21, 22), or the asialoglycoprotein recep-
tor (26), which is expressed on liver hepatocytes. Like DC-
SIGN and L-SIGN, the asialoglycoprotein receptor attaches
HCV through binding of glycan residues (galactose or N-acetyl-
galactosamine) on the viral glycoprotein E2.
In conclusion, our results show that HCV envelope glycopro-
tein E2 strongly binds to oligomeric C-type lectins in a high-
mannose N-glycan-dependent fashion. High affinity interac-
tion of viral glycoproteins with lectins might represent a
strategy by which enveloped viruses target to the site of repli-
cation and represents an interesting novel target for antiviral
drug development.
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